









Markets
/
Stocks
/
nasdaq-krys
/

Krystal Biotech Inc

KRYS

157.845USD

+3.795+2.46%

Market hours （ET）Quotes delayed by 15 min

4.57BMarket Cap

31.12P/E TTM



Krystal Biotech Inc

157.845

+3.795+2.46%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

1 / 507

Overall Ranking

12 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Buy

Current Rating

205.818

Target Price

+33.32%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. It is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include VYJUVEK, KB407, KB408, KB707, KB105, KB104, KB104, and KB301. Its commercial product VYJUVEK is a non-invasive, topical, redo sable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds. VYJUVEK is designed to treat DEB at the molecular level by providing the patient’s skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. KB407 is developed for the treatment of Cystic Fibrosis. KB408 is developed for the treatment of Alpha-1 Antitrypsin Deficiency. KB707 is developed for the treatment of solid tumors. KB105 is developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis.

Fairly Valued

The company’s latest PE is 30.18, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 32.63M shares, decreasing 3.24% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.82M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 9.31, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 96.04M, representing a year-over-year increase of 36.65%, while its net profit experienced a year-over-year increase of 146.23%.

Score

Industry at a Glance

Previous score

9.31

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.77

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.79

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 5.36, which is higher than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 30.18, which is 72.54% below the recent high of 52.07 and 149.09% above the recent low of -14.81.

Score

Industry at a Glance

Previous score

4.55

Change

0.81

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 1/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.50, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Krystal Biotech Inc is 202.00, with a high of 252.00 and a low of 166.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 12 analysts

Buy

Current Rating

205.818

Target Price

+33.60%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Krystal Biotech Inc

KRYS

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 9.18, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 162.43 and the support level at 141.20, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.17

Change

0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

1.583

Buy

RSI(14)

58.184

Neutral

STOCH(KDJ)(9,3,3)

78.368

Buy

ATR(14)

5.528

High Vlolatility

CCI(14)

116.291

Buy

Williams %R

18.417

Overbought

TRIX(12,20)

0.043

Sell

StochRSI(14)

83.409

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

150.436

Buy

MA10

147.607

Buy

MA20

147.853

Buy

MA50

147.481

Buy

MA100

143.269

Buy

MA200

156.383

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 112.75%, representing a quarter-over-quarter decrease of 0.45%. The largest institutional shareholder is The Vanguard, holding a total of 2.82M shares, representing 9.74% of shares outstanding, with 2.55% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

4.31M

+0.16%

BlackRock Institutional Trust Company, N.A.

3.63M

-2.77%

The Vanguard Group, Inc.

Star Investors

2.82M

-1.85%

Avoro Capital Advisors LLC

2.73M

+3.89%

Krishnan (Krish S)

1.67M

-1.47%

Krishnan (Suma M)

1.60M

+1.58%

State Street Global Advisors (US)

1.23M

-4.09%

Capital World Investors

954.47K

+8.56%

Soleus Capital Management, L.P.

441.76K

+23.27%

Braidwell LP

400.74K

+99.87%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 4.59, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.61. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.